title: Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.
abstract: Allosteric binding pockets in peptide-binding G protein-coupled receptors create opportunities for the development of small molecule drugs with substantial benefits over orthosteric ligands. To gain insights into molecular determinants for this pocket within type 1 and 2 cholecystokinin receptors (CCK1R and CCK2R), we prepared a series of receptor constructs in which six distinct residues in TM2, -3, -6, and -7 were reversed. Two novel iodinated CCK1R- and CCK2R-selective 1,4-benzodiazepine antagonists, differing only in stereochemistry at C3, were used. When all six residues within CCK1R were mutated to corresponding CCK2R residues, benzodiazepine selectivity was reversed, yet peptide binding selectivity was unaffected. Detailed analysis, including observations of gain of function, demonstrated that residues 6.51, 6.52, and 7.39 were most important for binding the CCK1R-selective ligand, whereas residues 2.61 and 7.39 were most important for binding CCK2R-selective ligand, although the effect of substitution of residue 2.61 was likely indirect. Ligand-guided homology modeling was applied to wild type receptors and those reversing benzodiazepine binding selectivity. The models had high predictive power in enriching known receptor-selective ligands from related decoys, indicating a high degree of precision in pocket definition. The benzodiazepines docked in similar poses in both receptors, with C3 urea substituents pointing upward, whereas different stereochemistry at C3 directed the C5 phenyl rings and N1 methyl groups into opposite orientations. The geometry of the binding pockets and specific interactions predicted for ligand docking in these models provide a molecular framework for understanding ligand selectivity at these receptor subtypes. Furthermore, the strong predictive power of these models suggests their usefulness in the discovery of lead compounds and in drug development programs.
authors.affiliation: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona 85259, USA.
authors.forename: Erin E
authors.initials: EE
authors.lastname: Cawston
authors.forename: Polo C H
authors.initials: PC
authors.lastname: Lam
authors.forename: Kaleeckal G
authors.initials: KG
authors.lastname: Harikumar
authors.forename: Maoqing
authors.initials: M
authors.lastname: Dong
authors.forename: Alicja M
authors.initials: AM
authors.lastname: Ball
authors.forename: Mary Lou
authors.initials: ML
authors.lastname: Augustine
authors.forename: Eyup
authors.initials: E
authors.lastname: Akgün
authors.forename: Philip S
authors.initials: PS
authors.lastname: Portoghese
authors.forename: Andrew
authors.initials: A
authors.lastname: Orry
authors.forename: Ruben
authors.initials: R
authors.lastname: Abagyan
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Sexton
authors.forename: Laurence J
authors.initials: LJ
authors.lastname: Miller
mesh_terms: D000495:Allosteric Site; D000595:Amino Acid Sequence; D000818:Animals; D001569:Benzodiazepines / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019556:COS Cells; D002522:Chlorocebus aethiops; D008024:Ligands; D008969:Molecular Sequence Data; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D017386:Sequence Homology, Amino Acid
chemical_list: D008024:Ligands; D011949:Receptors, Cholecystokinin; D001569:Benzodiazepines